Using Calcifediol to treat COVID-19 pneumonia
Inclusion of Calcifediol in the Hospital Therapeutic Protocol for Treatment of SARS-CoV-2 Disease (COVID-19). Mortality Analysis. Retrospective Study.
This study is testing whether adding calcifediol to the treatment of hospitalized patients with COVID-19 pneumonia can improve their recovery and reduce serious complications.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 275 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Complejo Hospitalario Universitario de Albacete Academic / other |
| Locations | 2 sites (Albacete and 1 other locations) |
| Trial ID | NCT06279910 on ClinicalTrials.gov |
What this trial studies
This observational study evaluates the effects of adding calcifediol to the treatment regimen of hospitalized patients with COVID-19 pneumonia. It aims to analyze patient outcomes, including mortality rates and ICU admissions, by reviewing medical records from the Complejo Hospitalario Universitario de Albacete. The study focuses on patients who have tested positive for SARS-CoV-2 and received calcifediol within the first 72 hours of hospitalization. The findings could provide insights into the potential benefits of calcifediol in managing severe COVID-19 cases.
Who should consider this trial
Good fit: Ideal candidates are hospitalized patients diagnosed with COVID-19 who have received at least the first dose of calcifediol within 72 hours of admission.
Not a fit: Patients who do not receive the full first dose of calcifediol within the specified time frame or have serious concurrent diseases may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could improve survival rates and reduce the need for intensive care in COVID-19 patients.
How similar studies have performed: While the use of calcifediol in COVID-19 treatment is being explored, this specific observational approach is relatively novel and has not been extensively tested in prior studies.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Admitted to the hospital "Complejo Hospitalario de la GAI de Albacete" 2. Meet the SARS-CoV-2 diagnostic criteria with positive PCR 3. They have completed at least the first dose of Calcifediol within the first 72 hours after admission, (according to protocol). Exclusion Criteria: 1. Patients who do not receive the full first doseof Calcifediol within the first 72 hours. 2. Patients for whom electronic medical record data cannot be collected. 3. Patients with other serious intercurrent diseases (eg advanced oncological pathology).
Where this trial is running
Albacete and 1 other locations
- Complejo Hospitalario Universitario de la Gerencia de Atención Integrada (GAI) de Albacete — Albacete, Spain (Recruiting)
- Maimónides Biomedical Research Institute of Córdoba (IMIBIC). — Cordoba, Spain (Withdrawn)
Study contacts
- Study coordinator: Jose A Blazquez, MD
- Email: jblazquez@sescam.jccm.es
- Phone: +34967597100
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.